Eric Rovner, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    uromedica
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    Valencia
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company:
    astellas
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Hologix
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Bluewind
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    Urovant
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Allergan
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Specialty Not Specified)
    Ineligible company:
    NextMed
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Medtronics
    Date added:
    Date updated:
    11/05/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    NIH/NIDDK
    Date added:
    Date updated:
    11/05/2024
Return to Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment Webcast (2022)